Singapore-based Hilleman Laboratories announces plans to advance an rVSV-based vaccine against the Bundibugyo strain of Ebola into human trials after World Health Organization experts identified it as the most promising candidate for the epidemic. (AFP via CNA) 2026 Ebola epidemic link embed save